Comprehensive genomic characterization defines human glioblastoma genes and core pathways
暂无分享,去创建一个
Joshua M. Korn | Christopher A. Miller | Derek Y. Chiang | Benjamin E. Gross | Nicholas J. Wang | Amy E. Hawkins | Brian H. Dunford-Shore | D. Absher | T. Fennell | K. Cibulskis | S. Gabriel | J. Mesirov | E. Lander | C. Sander | G. Sherlock | R. Wilson | R. Fulton | G. Weinstock | E. Mardis | R. Gibbs | P. Spellman | M. Bittner | R. Myers | T. Golub | L. Chin | G. Getz | M. Meyerson | Huy Nguyen | L. Fulton | J. Baldwin | Michael Reich | M. Berger | F. Collins | J. Brooks | A. Southwick | W. Gerald | C. Perou | T. Speed | J. Weinstein | P. Park | A. Lapuk | H. Feiler | J. Gray | M. Robinson | R. McLendon | A. Friedman | D. Bigner | Erwin G. Van Meir | D. Brat | Gena M Mastrogianakis | J. Olson | T. Mikkelsen | N. Lehman | K. Aldape | W. Yung | O. Bogler | S. Vandenberg | M. Prados | D. Muzny | M. Morgan | S. Scherer | A. Sabo | L. Nazareth | L. Lewis | O. Hall | Yiming Zhu | Yanru Ren | Omar Alvi | Jiqiang Yao | A. Hawes | S. Jhangiani | G. Fowler | A. Lucas | C. Kovar | A. Cree | H. Dinh | J. Santibanez | V. Joshi | M. Gonzalez-Garay | A. Milosavljevic | L. Donehower | D. Wheeler | C. Sougnez | Scott Mahan | Jane Wilkinson | L. Ziaugra | R. Onofrio | T. Bloom | R. Nicol | K. Ardlie | L. Ding | M. McLellan | J. Wallis | D. Larson | Xiaoqi Shi | R. Abbott | Ken Chen | D. Koboldt | M. Wendl | R. Meyer | Yuzhu Tang | Ling Lin | John R. Osborne | T. Miner | K. Delehaunty | C. Markovic | Gary W. Swift | W. Courtney | C. Pohl | S. Abbott | Shin Leong | C. Haipek | Heather K. Schmidt | M. Wiechert | T. Vickery | S. Scott | D. Dooling | A. Chinwalla | W. Winckler | R. Verhaak | M. Lawrence | Michael J. T. O’Kelly | James Robinson | G. Alexe | R. Beroukhim | S. Carter | Josh Gould | Supriya Gupta | J. Korn | C. Mermel | S. Monti | Melissa Parkin | Nicolas Stransky | B. Weir | L. Garraway | A. Protopopov | Jianhua Zhang | I. Perna | Sandy Aronson | N. Sathiamoorthy | Georgi Ren | Jun Yao | W. Wiedemeyer | Hyun Soo Kim | Won Kong Sek | Yonghong Xiao | I. Kohane | J. Seidman | R. Kucherlapati | P. Laird | L. Cope | J. Herman | D. Weisenberger | F. Pan | D. V. Berg | L. V. Neste | Mingyu Joo | K. Schuebel | S. Baylin | Jun Z. Li | S. Brady | A. Aggarwal | Tisha Chung | E. Purdom | L. Jakkula | H. Marr | S. Dorton | Gi Choi Yoon | Ju Han | A. Ray | V. Wang | S. Durinck | K. Vranizan | V. Peng | E. V. Name | G. Fontenay | J. Ngai | J. Conboy | B. Parvin | C. Brennan | N. Socci | A. Olshen | B. Taylor | A. Lash | N. Schultz | B. Reva | Yevgeniy Antipin | A. Stukalov | E. Cerami | Qingqing Wei | L. Qin | V. Seshan | Liliana Villafania | Magali Cavatore | L. Borsu | A. Viale | M. Ladanyi | D. Hayes | M. D. Topal | K. Hoadley | Yuan Qi | S. Balu | Yan Shi | Junyuan Wu | R. Penny | T. Shelton | E. Lenkiewicz | S. Morris | D. Beasley | Sheri Sanders | A. Kahn | R. Sfeir | Jessica Chen | D. Nassau | L. Feng | E. Hickey | A. Barker | D. Gerhard | J. Vockley | C. Compton | J. Vaught | P. Fielding | M. Ferguson | C. Schaefer | Jinghui Zhang | S. Madhavan | K. Buetow | P. Good | M. Guyer | B. Ozenberger | J. Peterson | E. Thomson | Audrey M. Southwick | Kornel E. Schuebel | Shannon T. Brady | Subha Madhavan | Vandita Joshi | S. Aronson | Larry Feng | Alexey Stukalov | Huy L. Nguyen | M. Reich | N. Stransky | Toby Bloom | R. Wilson | D. Muzny | Jane L. Peterson | Andrew Cree | J. Gray | Gabriele Alexe | Liliana B Villafania
[1] P. Humphrey,et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[2] C. James,et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[3] R. Neumann,et al. Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours. , 1995, Anticancer research.
[4] M. Dolan,et al. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. , 1995, Progress in nucleic acid research and molecular biology.
[5] D. Cooper,et al. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene , 1996, Human Genetics.
[6] C. Moorehead. All rights reserved , 1997 .
[7] M. Cayouette,et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. , 1997, The New England journal of medicine.
[8] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[9] P. Nürnberg,et al. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. , 2000, American journal of human genetics.
[10] Karlyne M. Reilly,et al. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects , 2000, Nature Genetics.
[11] G Mortier,et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects , 2000, Human mutation.
[12] I. Campbell,et al. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.
[13] M. Berger,et al. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. , 2003, Journal of neurosurgery.
[14] T. Golub,et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.
[15] Paul S Mischel,et al. Targeted Molecular Therapy of GBM , 2003, Brain pathology.
[16] Paul S Mischel,et al. Molecular Analysis of Glioblastoma: Pathway Profiling and Its Implications for Patient Therapy , 2003, Cancer biology & therapy.
[17] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[18] Finn Drabløs,et al. Alkylation damage in DNA and RNA--repair mechanisms and medical significance. , 2004, DNA repair.
[19] Andrew D. Yates,et al. Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.
[20] S. Horvath,et al. Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.
[21] M. Stratton,et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.
[22] Catherine L Nutt,et al. Genetic Alterations of Phosphoinositide 3‐kinase Subunit Genes in Human Glioblastomas , 2004, Brain pathology.
[23] Li Zhao,et al. Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.
[24] D. Botstein,et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[25] Dawen Zhao,et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. , 2005, Cancer cell.
[26] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[27] Yuri Kotliarov,et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.
[28] Gary L Gallia,et al. PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme , 2006, Molecular Cancer Research.
[29] L. Chin,et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. , 2006, Cancer research.
[30] P. Vogt,et al. Cancer-specific mutations in PIK3CA are oncogenic in vivo , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[31] T. Roberts,et al. Human tumor mutants in the p110alpha subunit of PI3K. , 2006, Cell cycle.
[32] Jayant P. Menon,et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.
[33] Tracy T Batchelor,et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.
[34] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[35] S. Gabriel,et al. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.
[36] Thomas D. Wu,et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.
[37] Bert Vogelstein,et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. , 2007, Science.
[38] Rebecca A Betensky,et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] M. Christmann,et al. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. , 2007, DNA repair.
[40] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[41] K. Kinzler,et al. The Structure of a Human p110a/p85a Complex Elucidates the Effects of Oncogenic PI3Ka Mutations , 2007 .
[42] Bert Vogelstein,et al. The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.
[43] Guy Cavet,et al. Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers" , 2007, Science.
[44] L. Mario Amzel,et al. The Structure of a Human p 110 a / p 85 a Complex Elucidates the Effects of Oncogenic PI 3 K a Mutations , 2007 .
[45] Guojun Wu,et al. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells , 2008, Breast Cancer Research and Treatment.
[46] P. A. Futreal,et al. Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment , 2007, Clinical Cancer Research.
[47] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[48] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[49] M. Bignami,et al. Role of mismatch repair and MGMT in response to anticancer therapies. , 2008, Anti-cancer agents in medicinal chemistry.
[50] R. Mason,et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. , 2008, Cancer research.
[51] K. Aldape,et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.
[52] E. Domany,et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Webster K. Cavenee,et al. Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development , 2008, Cancer cell.
[54] E. Kohn,et al. Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency , 2008, International journal of cancer.
[55] C. Sander,et al. Functional Copy-Number Alterations in Cancer , 2008, PloS one.